Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of “Moderate Buy” by Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and eighteen have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $294.50.

ALNY has been the subject of a number of recent research reports. Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Needham & Company LLC reissued a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $198.00 to $370.00 in a report on Friday, August 16th. JPMorgan Chase & Co. increased their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Finally, Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. This trade represents a 16.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Souders Financial Advisors raised its position in Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after purchasing an additional 36 shares in the last quarter. Huntington National Bank increased its stake in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the period. SYM FINANCIAL Corp raised its holdings in Alnylam Pharmaceuticals by 6.2% in the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 55 shares in the last quarter. Lindbrook Capital LLC grew its holdings in Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 57 shares in the last quarter. Finally, V Square Quantitative Management LLC increased its position in shares of Alnylam Pharmaceuticals by 21.9% in the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 60 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 8.7 %

Shares of Alnylam Pharmaceuticals stock opened at $235.56 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The firm has a market capitalization of $30.38 billion, a PE ratio of -89.91 and a beta of 0.39. The firm’s 50-day moving average price is $274.95 and its 200 day moving average price is $234.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the previous year, the company earned $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue was down 33.3% on a year-over-year basis. On average, sell-side analysts predict that Alnylam Pharmaceuticals will post -2.22 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.